Table 1.
Baseline Clinicopathologic Characteristics of Patients With Versus Without irAEs
| Characteristic | irAEs 73 (%) | No irAEs 110 (%) | p Value |
|---|---|---|---|
| Age, y, median (range) | 61 (47–84) | 66 (34–84) | 0.01 |
| Sex | 0.76 | ||
| Male | 33 (45.2) | 47 (42.7) | |
| Female | 40 (54.8) | 63 (57.3) | |
| Smoking status | 0.68 | ||
| Ever | 70 (95.9) | 107 (97.3) | |
| Never | 3 (4.1) | 3 (2.7) | |
| Stage at diagnosis | 0.62 | ||
| Limited | 23 (31.5) | 30 (27.3) | |
| Extensive | 50 (68.5) | 80 (72.7) | |
| ECOG PS | 0.23 | ||
| 0–1 | 52 (76.5) | 73 (67.0) | |
| ≥2 | 16 (23.5) | 36 (33.0) | |
| Not available | 5 | 1 | |
| Line of therapy for ICIs | 0.86 | ||
| 2nd | 53 (72.6) | 82 (72.6) | |
| ≥3rd | 20 (27.4) | 28 (25.5) | |
| Treatment received | < 0.001 | ||
| PD-(L)1 monotherapy | 32 (43.8) | 77 (70.0) | |
| PD-1 + CTLA-4 | 41 (56.2) | 33 (30.0) | |
| Cycles of ICI received, median (range) | 3.5 (1–71) | 2 (1–18) | < 0.001 |
| Any history of brain metastases before ICI | 0.87 | ||
| No | 49 (67.1) | 72 (65.5) | |
| Yes | 24 (32.9) | 38 (34.5) |
Note: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-L1, programmed death-ligand 1; PD-1, programmed cell death protein 1.